ADVFN ADVFN

Hot Features

Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Immatics NV

Immatics NV (IMTX)

9,65
-0,14
( -1,43% )
Mis à jour : 17:13:29

Immatics NV (IMTX) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
9,65
( -1,43% )
Prix Achat
9,64
Prix Vente
9,67
Volume échangé
51 033
9,625 Fourchette du Jour 10,04
5,05 Plage de 52 semaines 12,41
Cap du marché
Clôture Veille
9,79
Ouverture
9,92
Dernière Transaction
24
@
9.6677
Dernière heure de transaction
17:13:31
Volume financier
US$ 498 459
VWAP
9,7674
Volume moyen (3 m)
US$ 456 917
Actions en circulation
134 096 576
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-5,68
Bénéfice par action (BPA)
-1,71
Chiffre d'affairess (LTM)
37,3M
Bénéfice net (LTM)
-214,41M

À propos de Immatics NV

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two di... Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna’s PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. Show more

Secteur
Healthcare
Industrie
Biotechnology & Life Sciences
Site Web
Siège social
Tübingen, Germany
Fondé
-
Immatics NV est coté dans le secteur Healthcare de la NASDAQ avec le ticker IMTX. Le dernier cours de clôture d'Immatics NV était de US$9,79. Au cours de la dernière année, les actions de Immatics NV ont été négociées dans une fourchette de prix de US$ 5,05 à US$ 12,41.

Immatics NV compte actuellement 134 096 576 actions en circulation. La capitalisation boursière d'Immatics NV est de US$1,29 milliard. Immatics NV a un ratio cours/bénéfice (ratio PE) de -5.68.

IMTX Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-2.08-17.732310315411.7311.76899.5497850410.1569217CS
4-1.75-15.35087719311.411.949.5466816110.73459366CS
120.212.224576271199.4411.949.1348049710.6014902CS
26-0.53-5.2062868369410.1811.948.5547443810.26537139CS
523.6159.76821192056.0412.415.056119118.71500215CS
156-0.58-5.6695992179910.2313.773.35774408.78557618CS
260-2.63-21.416938110712.2816.33.34268558.9963008CS

IMTX - Frequently Asked Questions (FAQ)

What is the current Immatics NV share price?
The current share price of Immatics NV is US$ 9,65
How many Immatics NV shares are in issue?
Immatics NV has 134 096 576 shares in issue
What is the market cap of Immatics NV?
The market capitalisation of Immatics NV is USD 1,29B
What is the 1 year trading range for Immatics NV share price?
Immatics NV has traded in the range of US$ 5,05 to US$ 12,41 during the past year
What is the PE ratio of Immatics NV?
The price to earnings ratio of Immatics NV is -5,68
What is the cash to sales ratio of Immatics NV?
The cash to sales ratio of Immatics NV is 34,93
What is the registered address of Immatics NV?
The registered address for Immatics NV is Paul-Ehrlich-Strasse 15-19, Tübingen, Baden-Württemberg, 72076
What is the Immatics NV website address?
The website address for Immatics NV is www.immatics.com
Which industry sector does Immatics NV operate in?
Immatics NV operates in the Biotechnology & Life Sciences sector

IMTX Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion